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MicroRNAs (miRNAs), prominent types of small noncoding RNA, have been revealed as key regulators of
gene expression at the post-transcriptional level. Major advances in the understanding of miRNA biology
in the past decades include biogenesis pathways, principles of target gene regulation and identiﬁcation
of target transcripts. Of note, miRNAs can act as a switch or a ﬁne-tuner to control the level and function
of target genes, which reciprocally regulate miRNAs via miRNA response elements at 30 untranslated
regions. In addition to current knowledge about miRNA biogenesis and function, this review looks at
mounting evidence that aberrant expression of miRNAs in both the cerebral cortex and peripheral blood
mononuclear cells may underlie many of the molecular changes observed in psychiatric disorders.
Copyright  2013, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Since the last few decades of the 20th century, the central
dogma of molecular biology has been that the purpose of tran-
scribed RNA is to direct the assembly of proteins from amino acids.
Only a few exceptions to this paradigm are known. Examples
include ribosomal RNA and transfer RNA, both of which are func-
tional RNA macromolecules that do not code for protein, and viral
genomes that exist as or pass through an RNA phase as part of total
genome replication. However, more recent studies have uncovered
thousands of RNA species transcribed in the genome that serve as
regulatory elements for individual genes as well as gene networks.
These RNAs are collectively known as noncoding RNAs (ncRNAs),
which can interact with DNA, RNA, and protein molecules and
engage in diverse structure and functional activities. They also
have roles in nuclear organization, and transcriptional, post-
transcriptional, and epigenetic processes. Among them, one class
of small ncRNAsdthe microRNAs (miRNAs)dhas been found to be, Buddhist Tzu Chi General
ien, Taiwan. Tel.: þ886 38
ddhist Compassion Relief Tzu Chiquite phylogenetically extensive and conservative in eukaryotic
cells.
The miRNAs were ﬁrst recognized as “small temporal” antisense
RNAs controlling the timing of larval development in the nematode
Caenorhabditis elegans by Lee et al in 1993 [1]. Since then, more
novel genes coding for these small expressed RNAs have been
identiﬁed, and the term “microRNAs” was given to them in 2001
[2e4]. Averaging 22 nucleotides (nt) in length (19e25 nt for mature
miRNAs), these single-stranded RNAs, canonically derived from
longer primary transcripts (pri-miRNAs), bind to sequences called
microRNA response elements (MREs) with partial complementarity
on target mRNA, usually resulting in the repression of target gene
expression. Today, 1600 precursory genes and 2042 mature se-
quences of miRNAs have been identiﬁed in humans according to
the latest information from a microRNA database (miRBase 19,
released in August 2012). It is estimated that about two-thirds of
human protein-coding genes are under selective pressure to
maintain pairing to miRNAs, and are thus potential targets for
miRNAs [5].
The central nervous system is characterized by extraordinary
degrees of functional network connectivity and responsiveness to
interoceptive and environmental stimuli. It is now clear that these
features are mediated not only by the expression proﬁles, local-
ization, and translation of protein-coding genes, but also by miR-
NAs that have a diverse range of regulatory and functional roles inFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
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cesses. An adequate spatiotemporal coordination of gene-
regulatory networks in response to internal or external signals is
crucial to the normal development and function of the brain, and
inclusion of miRNAs in such regulatory mechanisms appears to
increase the precision of biological functionalities of the genes [6,7].
Moreover, many novel brain-speciﬁc miRNA families have
increasing diversity in nonhuman primates and humans, suggest-
ing that miRNA evolution is an ongoing process linked to greater
brain complexity [8]. In recent years, roles for speciﬁc miRNAs in
neuronal development, function, and dysfunction have been
demonstrated [9].
In this brief review, we summarize our current knowledge about
the principles of biogenesis and biological functions of miRNAs in
mammals, and then focus on evidence demonstrating the role of
miRNAs in psychiatric disorders.2. The biogenesis and turnover of miRNA
Initially, the pri-miRNA sequence is transcribed in a RNA poly-
merase II-dependent manner into a double-stranded RNA with
a stem-loop structure. The precursor genes coding for miRNAs are
frequently located in introns or intergenic regions of protein-
coding genes. Other miRNAs are transcribed as part of long
ncRNAs and are often arranged as clusters in the genome, which
leads to one pri-miRNA being subsequently processed into several
functional miRNAs. Following transcription, the RNase III endonu-
clease Drosha, in conjunction with Di George syndrome critical
region gene 8 (DGCR8), excises the pri-miRNA stem-loop, resulting
in a hairpin-shaped RNA molecule of 70e100 base pairs called an
miRNA precursor or pre-miRNA [10e12]. The pre-miRNAs are
speciﬁcally recognized by the nuclear export receptor Exportin 5
and exported in a Ran-GTP dependent manner [13,14].Fig. 1. Biogenesis of miRNAs. After transcription by RNA polymerase II, pri-miRNA is gene
complex. The cleavage product is a pre-miRNA hairpin, which is then exported to the cytop
processed by Dicer and accessory proteins such as TRBP to a short-lived miRNA duplex inte
usually degraded. The mature miRNA is loaded into a multi-protein complex to generate the
located predominantly within the 30-UTR region of mRNAs and can interfere with transla
syndrome critical region gene 8; FMRP ¼ fragile X mental retardation protein; GW182 ¼ gly
silencing complex; PABPC ¼ cytoplasmic poly-A binding protein; pre-miRNA ¼ precursor
binding protein; UTR ¼ untranslated region.In the cytoplasm, the pre-miRNAs are further cleaved by the
double-stranded RNA binding protein transactivation-responsive
RNA-binding protein and the RNase III enzyme Dicer. The result
of Dicer cleavage is an miRNA/miRNA* duplex ofw22 nt in length.
One strand of this duplex, the mature miRNA, is then transferred
and incorporated into the miRNA-induced silencing complex
(miRISC), while the other strand, the miRNA star strand (miRNA*),
is released and degraded. Generally, the strandwith less stable base
pairing at the 50 end is retained in the miRNA/miRNA* duplex. The
miRNA* strands are not always by-products or passengers of
miRNA biogenesis and can also be loaded intomiRISC to function as
mature miRNAs [15,16]. In mammals, the strand selection and
miRISC assembly is accomplished by a complex that contains Dicer,
transactivation-responsive RNA-binding protein, and argonaute
(AGO) proteins [17,18].
There are a number of cofactors or accessory proteins that act as
activators or repressors in the maturation of miRNAs. For example,
the two DEAD-box RNA helicases DDX5 and DDX17 (also known as
p68 and p72), identiﬁed as integral parts of the Drosha micro-
processor complex, are thought to stimulate processing of a subset
of pri-miRNAs by themselves [19] or by interacting with other
proteins such as SMADs and p53 [20,21]. The presence of LIN-28,
the best-studied negative regulator of miRNA biogenesis, can act
at both the Drosha and Dicer levels to block the expression of
mature “let-7” family miRNAs in embryonic stem cells and other
progenitor cells [22]. An overview of miRNA biogenesis is shown in
Fig. 1.
In contrast to miRNA biogenesis, regulation of the turnover and
decay of miRNAs is still largely unknown. It is generally thought
that miRNAs represent highly stable molecules, and long half-lives
of certain miRNAs in cells lines or organs have been found [23].
However, such slow turnover is unlikely to be a universal feature of
miRNAs as they often play a role in developmental transitions, or
act as on/off switches of gene expression, conditions that requirerated and subsequently cleaved in the nucleus by the Drosha/DGCR8 microprocessor
lasm by an Exportin 5/Ran-GTP dependent pathway. The pre-miRNA hairpin is further
rmediate. One strand is selected and becomes the mature miRNA, whereas the other is
miRISC. With the guide of mature miRNA, the miRISC binds to speciﬁc “seed” sequences
tion of the mRNA and reduce mRNA levels. AGO ¼ argonaute; DGCR8 ¼ Di George
cine-tryptophan protein of 182 kDa; miRNAs ¼ microRNAs; miRISC ¼ miRNA-induced
microRNA; pri-miRNA ¼ primary microRNA; TRBP ¼ transactivation-responsive RNA-
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some miRNAs has been reported in mouse retinal neurons and
primary dissociated neurons [24]. Notably, many, if not all miRNA
turnover in neurons seems to be activity dependent, suggesting
that active miRNA metabolism may be important for neuronal
function [25].
3. The mechanisms of action of miRNAs
The mechanisms used by miRNAs to regulate target gene
expression has been a controversial subject, as there is evidence for
target messenger RNA (mRNA) destabilization and translational
repression, and even activation of gene expression [26]. Regulation
of target gene expression by miRNAs is subjected to various levels
of control, and recent developments have added a level of com-
plexity; targets can reciprocally control the function, stability, and
expression of miRNAs. In this section, the conventional logic of
target regulation by miRNAs will be discussed ﬁrst, followed by an
introduction to the intertwined relationship between miRNAs and
the “competing endogenous” RNAs (ceRNAs).
3.1. Target regulation by miRNA
In principle, the sequence of the miRNA speciﬁes the target
mRNA sequence via perfect WatsoneCrick base-pairing between
nucleotides 2e8 (the seed region) of the miRNA and a comple-
mentary site in the 30 untranslated region (UTR) of the target
mRNA. The degree of complementarity between miRNA and mRNA
dictates the method of gene inhibition; perfect complementarity
results in AGO-mediated cleavage of the target mRNA, while mis-
matches result in translational repression, a reversible process that
may allow cells to store mRNAs in preparation for rapid translation
[27]. miRISC is the functional unit that induces miRNA-guided
translational repression or deadenylation and degradation in the
target mRNAs. AGO proteins, which directly interact with miRNAs,
and glycine-tryptophan protein of 182 kDa (GW182), the down-
stream effector in translational repression and/or deadenylation,
are key factors in the function of miRISC. Perfect pairing of an
miRNA and its target site supports endonucleolytic cleavage of
mRNA by AGO, leading to rapid degradation of the mRNA, which is
a common mechanism in plants but is much rarer in animals.
GW182 proteins can recruit the CCR4-NOT protein complex, which
removes the poly-A tail and dissociates the cytoplasmic poly-A
binding protein to make the mRNA susceptible to exonucleolytic
degradation when partial pairing occurs between the miRISC and
30-UTR sequence of the target mRNA [28]. There are also cases in
which miRNAs cause reduced protein but not mRNA levels, sug-
gesting that translation repression can be directed by miRISC. The
actual mechanism that blocks protein production is not clear.
Ribosome proﬁling, a recently developed technology to detect
mRNA fragments associated with ribosomes, can provide some
evidence for the inhibition of translational initiation or elongation
by miRISC, as well as for directed proteolysis of the peptide being
synthesized from the miRNA-targeted mRNA [29]. Recent work has
shown that the CCR4-NOT complex that is recruited by GW182 to
deadenylate target mRNAs also acts to repress the initiation of
translation [30e32].
Stimulated translation of targets by miRNAs has been reported
under certain circumstances [33,34]. For example, in conjunction
with the proteins AGO and FMRP (fragile X mental retardation
syndrome-related protein), miR-16 targets myt1 kinase mRNA and
activates its expression in Xenopus laevis oocytes [35]. A recent
study showed that miR-328 directly interacts with hnRNP E2,
a regulatory RNA binding protein, preventing it from blocking
translation of C/EBPamRNA [36]. In this case, rather than serving asthe guiding part of miRISC that decays its target, miR-328 acts as
a decoy to suppress the translational inhibitor hnRNP E2 and
restore translation of the hnRNP E2-targeted mRNAs. Overall,
miRNAs typically repress gene expression; whether positive regu-
lation of targets extends beyond the limited cases uncovered so far
remains to be seen.
In view of the regulatory mechanisms mentioned above, it
seems that miRNAs behave as a switch in target gene expression.
In fact, the typical magnitude of observed gene repression by
miRNAs is relatively small [37,38]. Mukherji et al performed
single-cell measurements and found that miRNAs can generate
thresholds in target gene expression [39]. When the relative
expression of the target gene is below the threshold, its protein
production is highly repressed. Near this threshold, the protein
expression responds sensitively to target mRNA input, which ﬁts
a molecular titration model. Therefore, miRNAs can behave both
as a switch in the target expression regime below the threshold,
and as a ﬁne-tuner in the sensitive transition between the
threshold and the minimal repression regime at relatively high
mRNA levels.
3.2. Regulation of miRNAs by target interactions
Regulation in the miRNA pathway is a two-way streetdnot only
can base pairing between an miRNA and its target result in
repressed target expression, but these interactions can also have an
impact on the levels of the miRNA. For example, artiﬁcial “miRNA
sponges” using multiple copies of a single MRE in tandem effec-
tively knock down the miRNA family sharing the same seed region
and derepress miRNA targets [40]. There are also “endogenous” or
“natural” sponges in cells from transcribed RNAs that containMREs.
Actually, all miRNA targets, including coding and noncoding tran-
scriptomes, can be endogenous sponges of miRNAs.
Besides regulating the stability of miRNAs via direct base-
pairing interactions, these sponges can inﬂuence one another’s
level by competing for a limited pool of miRNAs. Salmena et al
proposed a hypothesis of ceRNA to describe how mRNAs, tran-
scribed pseudogenes and ncRNAs “talk” to each other using MREs
as letters of a new language [41]. By presenting target sites for the
same miRNAs, ceRNAs mutually regulate each other’s expression
and form a large-scale regulatory network across the tran-
scriptome. Experimental evidence supporting the ceRNA
hypothesis includes the observation that overexpression of the
30-UTR of PTENP1, the pseudogene of phosphatase and tensin
homolog (PTEN) tumor suppressor gene, increases levels of PTEN
and growth inhibition in a DICER-dependent manner [42]. That is,
PTENP1 is biologically active as it can regulate cellular levels of
PTEN and exert a growth-suppressive role by acting as a decoy for
PTEN-targeting miRNAs. Another example in Arabidopsis thaliana
demonstrated that the ncRNA phosphate starvation 1 sequesters
miR-399 and results in attenuation of miR-399-mediated protein-
coding gene degradation by mimicking its target site, a phenom-
enon called “target mimicry” [43]. Large-scale analysis of gene
expression and matched miRNA proﬁles in human gliomas also
lend support to the idea that thousands of transcripts may be
acting as miRNA target decoys [44]. Notably, the ceRNA hypoth-
esis may help explain the recently identiﬁed expression of distinct
RNAs from 30-UTRs [45]. Instead of acting as cis-regulatory ele-
ments that alter the stability of their own transcripts, 30-UTRs
may act in trans to modulate gene expression through miRNA
binding. As proposed by the ceRNA hypothesis, events that can
alter the abundance or sequence of a particular transcript are
possible to induce “coding-independent” effects via interactions
with miRNAs and contribute to the pathological process of dis-
eases (Fig. 2).
Fig. 2. ceRNA logic and coding-independent regulation. (A) RNA molecules can communicate with each other through miRNA and MREs at 30-UTRs. For example, one of the MREs
(red circle) at the 30-UTR of RNA X can not only function in cis to regulate RNA X itself but also in trans to regulate RNA Y that shares similar MREs by the same acting miRNA. RNA X
and Y are acting as ceRNA mutually. (B) Genomic alterations such as copy number variations can alter the abundance of a particular transcript, and these events are possible to
induce “coding-independent” effects (e.g., up- or downregulation of other transcripts) by altering the levels of shared miRNAs. ceRNA ¼ competing endogenous RNA;
miRNAs ¼ microRNAs; MREs ¼ miRNA response sequences; UTRs ¼ untranslated regions.
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Psychiatric disorders, including schizophrenia, autistic disor-
ders, mood disorders (e.g., bipolar and depressive disorders), and
anxiety disorders (e.g., panic, phobic, and post-traumatic stress
disorders), are a major burden on both patients and society. The
ability of miRNAs to have a broad effect on gene regulation and
functional pathways has important implications for psychiatric
disorders, which have been characterized by complex genetics and
multi-pathway dysregulation. Recent studies on miRNA expression
proﬁling of brain tissue and peripheral blood from patients with
schizophrenia and bipolar disorder, as well as studies using animal
behavioral models to explore the molecular mechanisms of some
candidate miRNAs in psychosis, have indicated that miRNAs may
serve as disease biomarkers and represent new therapeutic targets
in psychiatry (Table 1).
4.1. miRNA dysregulation in schizophrenia
Several studies have examined the expression proﬁles of miR-
NAs in postmortem gray matter of individuals with schizophrenia
utilizing a caseecontrol approach [46e52]. Collectively, these
studies have identiﬁed many dysregulated miRNAs associated with
schizophrenia. However, while some have displayed consistent
changes across independent studies, many others have not. A total
of 16 miRNAs have been associated with consistently increased
expression (miR-105, miR-128a, miR-15a/b, miR-16, miR-17, miR-
199a*, miR-20a, miR-222, miR-34a, miR-452*, miR-486, miR-487a,
miR-502, miR-652, miR-7) and 11 miRNAs with consistently
decreased expression (miR-106b, miR-151, miR-20b, miR-224, miR-
30a/b/d/e, miR-383, miR-432, miR-505) in multiple studies using
human postmortem brains. Some miRNAs, such as miR-212, and
miR-26b, are consistently reported to display signiﬁcantly altered
expression, except in opposing directions [53]. The discrepancies in
the results can be attributed to technical variations such as tissue
preparation, sampling region differences, RNA isolation methods,ampliﬁcation, array platform, chemistry, and normalization
methods. In addition, the type and duration of antipsychotic med-
ication, genetic heterogeneity and diagnostic instability are factors
that certainly could account for the bias among different studies.
Investigation of miRNAs from peripheral blood mononuclear
cells (PBMCs) is a potential clinical application in schizophrenia.
First, PBMCs are more homogenous than brain tissue and can be
collected in large numbers from living patients. Second, although
the major disordered organ in schizophrenia is the brain, it is
plausible that the miRNA expression signature in PBMCs may
reﬂect not only disease-associated systemic changes but also
immunological risk factors relevant to the underlying biological
mechanism of schizophrenia. Using the expression proﬁles of
PBMCs, a research group from Taiwan identiﬁed peripheral pat-
terns of miRNAs that could have utility as biomarkers for schizo-
phrenia and associated endophenotypes [54]. Last but not least,
PBMCs are a common source for DNA isolation and subsequent
gene sequence and genome structure studies. Thus, experiments in
genetic linkage, genome-wide association studies (GWAS) and copy
number variations can be carried out with the same samples from
miRNAs expression studies. Gardiner et al applied this method and
revealed that a subgroup of dysregulated miRNAs were transcribed
from a single imprinted locus at the maternally expressed DLK1-
DIO3 region on chromosome 14q32 [55].
Individuals with 22q11.2 microdeletions are at high risk of
developing schizophrenia. With a cognitive deﬁcit mouse model,
Stark et al showed that abnormal miRNA biogenesis due to DGCR8
gene haploinsufﬁciency played a key role in a 22q11-deletion [56].
A number of studies have tested the association of miRNA poly-
morphisms or tag single nucleotide polymorphisms (SNPs) and
schizophrenia [57e59], and perhaps the most exciting miRNA gene
to show genetic association in a recent “mega-analysis” of GWAS
was miR-137 [60]. The functional signiﬁcance of miR-137 suscep-
tible variants in schizophrenia and other mental illnesses have also
been surveyed with consistent impacts on neural abnormalities
and cognitive deﬁcits [61e64]. In miR-137 studies for example,
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ages, and in vitro and in vivo disease model studies could shed some
light on the roles and mechanisms of miRNA dysregulation in
schizophrenia.
4.2. miRNA dysregulation in autism and mood and anxiety
disorders
Similar to schizophrenia, dysregulation of miRNAs has been
investigated in other major psychiatric disorders such as autism,
bipolar and unipolar depression, and anxiety but there are fewer
reported studies (Table 1). To identify a set of differentially
expressed miRNAs in autistic patients, Abu-Elneel et al used post-
mortem cerebellar cortex tissue [65], while Talebizadeh et al and
Sarachana et al used lymphoblastoid cell lines (LCLs) derived fromTable 1
MicroRNAs associated with psychiatric disease.
Disease Study material/methods Speci
Schizophrenia Postmortem brain (DLPFC,BA9)/microarray Huma
Postmortem brain (STG,BA22)/microarray Huma
PFC and HPC of 22q11.2 hemizygous deletion/
microarray
Mous
Postmortem brain (STG,BA22)/microarray Huma
Postmortem brain (DLPFC,BA9)/microarray Huma
Blood (59 X-linked miRNA genes)/resequencing Huma
Postmortem brain (PFC,BA10)/microarray Huma
Postmortem brain (DLPFC,BA46)/Tagman
low density array
Huma
PBMCs/microarray Huma
PBMCs/microarray Huma
Postmortem brain (DLPFC,BA9)/realtime qPCR
(Taqman assay)
Huma
Postmortem brain (DLPFC,BA46)/microarray Huma
NA./mega-analysis of GWAS Huma
Bipolar disorder Postmortem brain (DLPFC,BA46)/Tagman
low density array
Huma
Postmortem brain (DLPFC,BA9)/realtime qPCR
(Taqman assay)
Huma
HPC, after long-term lithium and valproate
administration/microarray
Rat
LCLs from bipolar patients, after 4-day lithium tx/
realtime qPCR (Taqman assay)
Huma
Autism LCLs from autistic subjects/microarray Huma
LCLs from autistic subjects/microarray Huma
Panic disorder NA (case-control from Spanish, Finnish &
Estonian)/miR-SNP
Huma
BA ¼ Brodmann’s area; DLPFC ¼ dorsolateral prefrontal cortex; GWAS ¼ genome-wid
SNP ¼ single nucleotide polymorphisms tagging microRNA; PBMCs ¼ peripheral blood mindependent caseecontrol cohorts [66,67]. The upregulation of
miR-23a was the only ﬁnding in common in these three studies.
Moreau et al revealed more pronounced underexpression of 24
miRNAs in the prefrontal cortex of patients with bipolar disorder
than in schizophrenic and healthy control groups [51]. Similarly,
Smalheiser et al reported that 21 miRNAs were signiﬁcantly
downregulated in the prefrontal cortex of depressed suicide sub-
jects [68]. Using SNPs tagging human miRNA regions, Muiños-
Gimeno et al reported the ﬁrst study that showedmiR-22, miR-138-
2, miR-148a, and miR-488 were associated with panic disorder, one
of the anxiety disorders, in Spanish and Finnish patients [69].
In addition to traits or states of diseases, the therapeutic effects
of psychotropic medications may also be mediated by miRNAs.
Zhou et al found that in vitro lithium and valproic acid treatment
differentially regulated 37 and 31 miRNAs, respectively, with eightes Disease-associated miRNA (miR-) Reference
n Up-regulated: 106b [46]
Down-regulated: 7, 20b, 24, 26b, 29a, 29b, 29c, 30a, 30b,
30d, 30e, 92, 195, 212, 9*
n Up-regulated: 181b [47]
e Down-regulated: 185, 134, 674, 540, 106b, 140*, 194,
325, 494, 362, 409, 323, 669a, 151, 18, 532, 673, 674*,
224, 491, 93, 383, 212, 422b, 708
[56]
n Up-regulated: let-7e, 107, 125b, 128a, 128b, 129, 130a,
133b, 138, 146b, 148a, 150, 152, 155, 15a, 15b, 16, 17-
3p, 17-5p, 181b, 195, 197, 199a*, 19a, 20a, 222, 23a, 24,
26b, 27b, 28, 296, 328, 330, 335, 338, 339, 340, 373*,
381, 409-5p, 432*, 452*, 455, 484, 485-5p, 486, 487a,
489, 494, 499, 502, 517a, 517c, 518b, 519d, 520a*, 520g,
9*, 99a
[49]
n Up-regulated: let-7d, 101, 105, 107, 126*, 128a, 153,
15a, 15b, 16, 181a, 181b, 181d, 184, 195, 199a, 20a, 219,
223, 26b, 27a, 29c, 302a*, 302b*, 31, 33, 338, 409-3p,
512-3p, 519b, 7
[49]
n X-linked private mutations in schizophrenia: 7f-2, 188-
3p, 325-3p, 509-3p, 660
[57]
n Down-regulated: 30e, 195 [48]
n Up-regulated: 132, 132*, 154*, 212, 34a, 544, 7 [50]
n Up-regulated: 34a, 449a, 548d, 564, 572, 652 [54]
Down-regulated: 432
n Down-regulated: 107, 134, 31, 431, 433, 487b, 99b [55]
n Up-regulated: 193b, 545, 639 [51]
Down-regulated: 33, 106b, 138, 151, 210, 22, 324-3p,
338, 339, 425
n Up-regulated: 328, 17-5p, 134, 652, 382, 107 [52]
n Risk loci: 137 [60]
n Up-regulated: 133b, 145, 145*, 154, 22*, 504, 889 [50]
Down-regulated: 32, 140-3p, 29a, 874, 454*, 520c-3p,
573, 767-5p
n Down-regulated: 33, 330, 192, 193a, 193b, 545, 138,
151, 210, 324-3p, 22, 425, 181a, 106b, 301, 27b, 148b,
338, 639, 15a, 186, 99a, 190, 339
[51]
Up-regulated: 144 [70]
Down-regulated: 34a, let-7b, let-7c, 30c, 128a, 221, 24a
n Up-regulated: 15a, 152, 221 [71]
Down-regulated: 494
n Up-regulated: 23a, 23b, 132, 146a, 146b, 663 [66]
Down-regulated: 92, 320, 363
n Up-regulated: 185, 103, 107, 29b, 194, 524, 191, 376a,
451, 23b, 195, 342, 23a, 186, 25, 519c, 346, 205, 30c, 93,
106b
[67]
Down-regulated: 182, 136, 518a, 153, 520b, 455, 326,
199b, 211b, 132, 495, 16, 190, 219, 148b, 189, 133b,
100b, 367, 139
n Risk loci: 22, 339, 138-2, 148a, 488 [69]
e association study; HPC ¼ hippocampus; LCLs ¼ lymphoblastoid cell lines; miR-
ononuclear cells; PFC ¼ prefrontal cortex; STG ¼ superior temporal gyrus.
Y.-L. Chao, C.-H. Chen / Tzu Chi Medical Journal 25 (2013) 1e76miRNAs in common [70]. Chen et al examined miRNA expression
in LCLs derived from bipolar patients and unaffected siblings, and
identiﬁed alterations in the expression of several miRNAs follow-
ing lithium treatment [71]. Fluoxetine (Prozac), a well-known se-
lective serotonin reuptake inhibitor antidepressant was recently
shown to increase miR-16 levels in serotonergic raphe nuclei,
which targets the serotonin transporter and promotes hippocam-
pal neurogenesis [72,73]. Taken together, investigations of dynamic
changes of miRNA expression during disease progression and re-
covery may provide more insight into the underlying patho-
physiology of psychiatric disorders, and new therapeutic targets as
well [74].
5. Summary and future directions
The ability of miRNAs to ﬁne-tune and switch the activity of
entire biological pathways makes them key regulators in a range of
biological processes, including cell fate determination, tissue dif-
ferentiation and organismal development. It is noteworthy that the
biological inﬂuences of miRNAs are not restricted to processes
within cells: they can act inside a cell between cellular organelles
and compartments, or outside cells between different tissues and
systems, and even outside living organisms between different
kingdoms. For example, nuclear miR-181c can translocate into the
mitochondria and regulate mitochondrial genome expression in
cardiac myocytes [75], while exogenous plant miRNAs in food (e.g.,
miR-168a from rice) can regulate the expression of target genes in
mammals [76]. The full scope and power of the biological in-
ﬂuences of miRNAs and other ncRNAs remain to be seen.
The diagnosis of psychiatric disorders is currently based exclu-
sively on behavioral signs and symptoms assessed by qualiﬁed
psychiatrists. Using a molecular signature could not only reﬁne
a diagnosis but also facilitate earlier intervention. Peripheral
miRNA-based biomarkers have already been shown useful in the
clinical stratiﬁcation of cancer and have even greater prognostic
signiﬁcance than mRNAs [77]. Moreover, a recent study showed
that miRNAs could induce conversion of human ﬁbroblasts to
neurons [78], which would be a promising way to obtain neuronal
tissues from patients with neuropsychiatric disorders to help
development of novel drugs. Studies on miRNA dysregulation are
increasing rapidly, and this emerging ﬁeld is anticipated to affect
clinical research, diagnosis, and therapy in psychiatry profoundly.
Future work will be necessary to unravel a more complete picture
of dysregulated miRNAs and test their potential for clinical appli-
cations in psychiatric disorders.
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